XOMA (NASDAQ:XOMA) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $74.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com raised XOMA to a sell rating in a research report on Wednesday, August 16th.

XOMA Price Performance

XOMA stock opened at $17.71 on Wednesday. XOMA has a 12 month low of $13.68 and a 12 month high of $26.00. The firm has a market cap of $203.19 million, a PE ratio of -6.58 and a beta of 0.87. The firm has a 50 day simple moving average of $15.66 and a 200 day simple moving average of $17.96.

Institutional Trading of XOMA

Several hedge funds and other institutional investors have recently modified their holdings of XOMA. UBS Group AG lifted its position in shares of XOMA by 9,318.8% in the third quarter. UBS Group AG now owns 1,507 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,491 shares in the last quarter. Barclays PLC acquired a new position in shares of XOMA in the second quarter worth $28,000. BNP Paribas Arbitrage SNC acquired a new position in shares of XOMA in the second quarter worth $36,000. Bank of America Corp DE increased its stake in shares of XOMA by 40.7% in the fourth quarter. Bank of America Corp DE now owns 2,380 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 689 shares during the last quarter. Finally, California State Teachers Retirement System acquired a new position in shares of XOMA in the second quarter worth $46,000. Institutional investors and hedge funds own 65.35% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.